Fourteen European countries have joined forces to lower the price of a new drug intended to treat hepatitis C. Gilead, the American laboratory which markets this new treatment, was currently planning to charge Sovaldi 56.000 euros per patient, or 280 times its manufacturing cost.
Guest of BFM TV, Marisol Touraine said that this union was a first. "I launched an initiative, which was a first, a few weeks ago in Brussels, to mobilize all European countries and to ensure that we join forces to influence price negotiations with this laboratory. American, explained the Minister of Health. And, for the first time, 14 European countries have made a commitment together."
The Minister of Health affirmed that she was committed to lowering the price: “We will negotiate country by country because that is how it is, but by exchanging our information and discussing between European countries. The price will come down, we are committed to that."
Thanks to this treatment, hepatitis C disappears in 90% of cases, which represents "a considerable therapeutic advance", in the words of Marisol Touraine.
source: Lexpress.fr
Further information :
Terms & Conditions
Subscribe
Report
My comments